- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04918121
A Study of Yutiq Steroid Insert During Glaucoma Tube Implant Surgery
September 21, 2023 updated by: Sanjay Asrani
This is a pilot study, which will include approximately five eyes of 5 patients.
This study proposes that a sustained release steroid insert (Yutiq)1 be implanted along with a glaucoma drainage device (Ahmed Glaucoma Valve (AGV) Model FP7) when the patient is undergoing glaucoma tube implant surgery or combined glaucoma tube implant and cataract surgery.
The primary aim of this study is to assess the safety and efficacy (controlling intraocular pressure) of the Yutiq inserts to reduce post-operative scarring in surgical glaucoma patients.
It is expected that post-operative week 12 onwards there will be a clinically and statistically significant lower IOP in the study eyes than eyes in a group undergoing the same surgery without the Yutiq insert.
The estimated duration of the present study is 3 years.
Study Overview
Study Type
Interventional
Enrollment (Estimated)
5
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Sarah Jones
- Phone Number: 1-919-681-6584
- Email: sarah.jones1@duke.edu
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Recruiting
- Duke Eye Center
-
Contact:
- Sanjay Asrani, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- At least 18 years old at time of consent.
- Patient being consented for either glaucoma tube implant surgery in pseudophakic eyes or being consented for cataract surgery with glaucoma tube implant surgery.
- Diagnosis of any type of glaucoma except inflammation associated glaucomas such as with co-existing uveitis or neovascular glaucoma.
- Negative urine pregnancy test at baseline for women of childbearing potential.
- Subjects who are willing and able to comply with scheduled visits, treatment plan and other study procedures and are able to provide an informed consent document signed and dated by the subject
Exclusion Criteria:
- Allergy to corticosteroids or any component of Yutiq insert.
- Patients with active or suspected ocular or periocular infections including most viral diseases such as herpes simplex, vaccinia, varicella, mycobacterial infections and fungal diseases.
- History of systemic immunosuppressive therapy or the possible need thereof such as patients with rheumatoid arthritis, lupus or transplant (systemic or eye)
- Previous history of tube erosion in the same or the other eye
- Eyes receiving anti-VEGF therapy in the study eye
- Media opacity precluding evaluation of retina and optic nerve in the study eye.
- History of steroid induced glaucoma
- Ocular surgery in the study eye within 3 months prior to enrollment.
- Patients who have tested positive for human immune deficiency virus.
- Pregnant or lactating females or females of child bearing age who are not willing to use contraception for the duration of the study.
- Patients for whom any of the protocol procedures may pose a special risk not outweighed by the potential benefits of participating in the study.
- Patients who are unlikely to comply with the study protocol.
- Any severe acute or chronic medical or psychiatric condition that could increase the risk associated with study participation or could interfere with the interpretation of study results and, in the judgment of the investigator, could make the patient inappropriate for entry into this study.
- Treatment with an investigational drug or device within 30 days preceding the glaucoma surgery.
- Any eye needing urgent glaucoma surgery i.e. within 5 days of the baseline visit (to allow time for patients to review the study documents).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Yutiq
A sustained-release steroid insert (Yutiq) will be implanted along with a glaucoma drainage device (Ahmed Glaucoma Valve (AGV) Model FP7) when the patient is undergoing glaucoma tube implant surgery or combined glaucoma tube implant and cataract surgery.
|
a sustained-release steroid insert (Yutiq)
|
No Intervention: Control
Non-study eye will not receive the Yutiq insert
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in IOP measured using Goldman applanation tonometry
Time Frame: week 12, month 6, month 12, month 18, month 24, month 30 , month 36
|
IOP in study eyes compared to eyes undergoing the same surgery without the Yutiq insert
|
week 12, month 6, month 12, month 18, month 24, month 30 , month 36
|
Change in IOP measured using tonopen/Icare
Time Frame: week 12, month 6, month 12, month 18, month 24, month 30 , month 36
|
IOP in study eyes compared to eyes undergoing the same surgery without the Yutiq insert
|
week 12, month 6, month 12, month 18, month 24, month 30 , month 36
|
Medications usage as measured by medical record abstraction
Time Frame: week 12
|
Number of medications to control IOP in the study eye
|
week 12
|
Medications usage by medical record abstraction
Time Frame: month 6
|
Number of medications to control IOP in the study eye
|
month 6
|
Medications usage by medical record abstraction
Time Frame: month 12
|
Number of medications to control IOP in the study eye
|
month 12
|
Medications usage by medical record abstraction
Time Frame: month 18
|
Number of medications to control IOP in the study eye
|
month 18
|
Medications usage by medical record abstraction
Time Frame: month 24
|
Number of medications to control IOP in the study eye
|
month 24
|
Medications usage by medical record abstraction
Time Frame: month 30
|
Number of medications to control IOP in the study eye
|
month 30
|
Medications usage by medical record abstraction
Time Frame: month 36
|
Number of medications to control IOP in the study eye
|
month 36
|
Days on Steroid therapy by medical record abstraction
Time Frame: week 12
|
Total number of days of topical steroid therapy postoperatively
|
week 12
|
Days on Steroid therapy by medical record abstraction
Time Frame: month 6
|
Total number of days of topical steroid therapy postoperatively
|
month 6
|
Days on Steroid therapy by medical record abstraction
Time Frame: month 12
|
Total number of days of topical steroid therapy postoperatively
|
month 12
|
Days on Steroid therapy by medical record abstraction
Time Frame: month 18
|
Total number of days of topical steroid therapy postoperatively
|
month 18
|
Days on Steroid therapy by medical record abstraction
Time Frame: month 24
|
Total number of days of topical steroid therapy postoperatively
|
month 24
|
Days on Steroid therapy by medical record abstraction
Time Frame: month 30
|
Total number of days of topical steroid therapy postoperatively
|
month 30
|
Days on Steroid therapy by medical record abstraction
Time Frame: month 36
|
Total number of days of topical steroid therapy postoperatively
|
month 36
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Sanjay Asrani, MD, Duke Eye Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 20, 2021
Primary Completion (Estimated)
December 1, 2024
Study Completion (Estimated)
December 1, 2024
Study Registration Dates
First Submitted
June 2, 2021
First Submitted That Met QC Criteria
June 2, 2021
First Posted (Actual)
June 8, 2021
Study Record Updates
Last Update Posted (Actual)
September 22, 2023
Last Update Submitted That Met QC Criteria
September 21, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00106901
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glaucoma
-
Imperial College Healthcare NHS TrustIRIDEX CorporationNot yet recruitingGlaucoma | Glaucoma, Open-Angle | Glaucoma, Angle-Closure | Glaucoma, Neovascular | Glaucoma Eye | Glaucoma Secondary | Glaucoma Traumatic | Glaucoma Uveitic
-
Wills EyeIOP OphthalmicsTerminatedPrimary Open Angle Glaucoma | Neovascular Glaucoma | Uveitic Glaucoma | Pseudoexfoliation Glaucoma | Primary Angle Closure Glaucoma | Pigmentary Glaucoma | Traumatic GlaucomaUnited States
-
Centre hospitalier de l'Université de Montréal...CompletedGlaucoma | Glaucoma, Open-Angle | Glaucoma, Neovascular | Glaucoma Eye | Glaucoma and Ocular Hypertension | Glaucoma, Uncompensated | Glaucoma SecondaryCanada
-
Pro Top & Mediking Company LimitedCompletedOpen Angle Glaucoma | Neovascular Glaucoma | Angle Closure Glaucoma | Uveitis Glaucoma | Young Age Glaucoma | High Risk PatientEstonia
-
Sanoculis LtdCompletedPrimary Open Angle Glaucoma | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaIsrael
-
Bausch & Lomb IncorporatedNicOx Inc.CompletedPrimary Open Angle Glaucoma | Ocular Hypertension | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaUnited States
-
Sensimed AGCompletedPrimary Open Angle Glaucoma | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaFrance
-
Ivantis, Inc.CompletedPrimary Open Angle Glaucoma | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaUnited States
-
Wills EyeOptovueCompletedPrimary Open-angle Glaucoma | Normal Tension Glaucoma | Glaucoma; DrugsUnited States
-
iSTAR MedicalInternational Drug Development InstituteActive, not recruitingGlaucoma, Open-Angle Glaucoma EyeIndia, Panama
Clinical Trials on Yutiq 0.18 MG Drug Implant
-
Texas Retina AssociatesEye Point PharmaceuticalsRecruitingUveitis, Anterior | Uveitis | Uveitis, Posterior | Uveitis, IntermediateUnited States
-
Alimera SciencesCBCC Global ResearchRecruitingUveitis, PosteriorUnited States
-
GlaxoSmithKlineCompleted
-
Galeno Desenvolvimento de Pesquisas ClínicasSocraTec R&D GmbHCompleted
-
Luye Pharma Group Ltd.Not yet recruiting
-
University of PennsylvaniaRecruitingSickle Cell DiseaseUnited States
-
AstraZenecaWithdrawn
-
University of MiamiEmpower Research IncCompleted
-
Chong Kun Dang PharmaceuticalCompletedCardiovascular DiseasesKorea, Republic of
-
NeuroActiva, Inc.UnknownSevere Acute Respiratory Syndrome | Covid19 | Corona Virus Infection | Severe Acute Respiratory Syndrome (SARS) Pneumonia | Neurodegeneration | Neuroinflammatory Response | Severe Acute Respiratory Infection | Severe Acute Respiratory Syndrome of Upper Respiratory TractUnited States